Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

The policy review presents recommendations from the International Myeloma Working Group for the treatment of relapsed and refractory multiple myeloma. ​ Based on phase 2 and phase 3 trial results, the recommendations are intended for patients who have received one or more previous lines of therapy. ​ The challenges in selecting the optimal treatment strategy, including the availability of different approved agents and issues of drug access, are discussed. ​ The document emphasizes the need for more data on the efficacy of different regimens in specific patient populations. ​ Specific recommendations are provided for the treatment of relapsed and refractory disease in patients who have received one previous line of therapy, including preferred options, alternatives, and other options based on clinical trial outcomes. ​

Important Points:

1. Recommendations for the treatment of relapsed and refractory multiple myeloma are presented. ​​
2. The recommendations are based on phase 2 and phase 3 trial results. ​
3. Intended for patients who have received one or more previous lines of therapy. ​
4. Challenges in selecting the optimal treatment strategy are discussed.
5. Availability of different approved agents and issues of drug access are addressed. ​
6. More data is needed on the efficacy of different regimens in specific patient populations. ​
7. Specific recommendations are provided for patients who have received one previous line of therapy. ​
8. Recommendations include preferred options, alternatives, and other options based on clinical trial outcomes. ​

Authors:

Prof Philippe Moreau, MD, Prof Shaji K Kumar, MD,  Prof Jesús San Miguel, MD,  Faith Davies, MD,  Elena Zamagni, MD,  Nizar Bahlis, MD,  Prof Heinz Ludwig, MD,  Prof Joseph Mikhael, MD,  Prof Evangelos Terpos, MD,  Fredrik Schjesvold, MD,  Prof Thomas Martin, MD,  Prof Kwee Yong, MD,  Brian G M Durie, MD,  Prof Thierry Facon, MD,  Prof Artur Jurczyszyn, MD,  Surbhi Sidana, MD,  Prof Noopur Raje, MD,  Prof Niels van de Donk, MD,  Prof Sagar Lonial, MD,  Prof Michele Cavo, MD,  Prof Sigurdur Y Kristinsson, MD,  Prof Suzanne Lentzsch, MD,  Prof Roman Hajek, MD,  Prof Kenneth C Anderson, MD,  Prof Cristina João, MD,  Prof Hermann Einsele, MD,  Prof Pieter Sonneveld, MD,  Prof Monika Engelhardt, MD,  Prof Rafael Fonseca, MD, Annette Vangsted, MD,  Prof Katja Weisel, MD,  Rachid Baz, MD,  Vania Hungria, MD,  Jesus G Berdeja, MD,  Fernando Leal da Costa, MD,  Prof Angelo Maiolino, MD,  Prof Anders Waage, MD,  Prof David H Vesole, MD,  Enrique M Ocio, MD,  Prof Hang Quach, MD,  Prof Christoph Driessen, MD,  Prof Joan Bladé, MD,  Prof Xavier Leleu, MD,  Eloisa Riva, MD,  Prof Peter Leif Bergsagel, MD,  Prof Jian Hou, MD,  Prof Wee Joo Chng, MD,  Ulf-Henrik Mellqvist, MD,  Dominik Dytfeld, MD,  Prof Jean-Luc Harousseau, MD,  Prof Hartmut Goldschmidt, MD,  Jacob Laubach, MD,  Prof Nikhil C Munshi, MD,  Prof Francesca Gay, MD,  Prof Meral Beksac, MD,  Luciano J Costa, MD,  Martin Kaiser, MD,  Prof Parameswaran Hari, MD,  Prof Mario Boccadoro, MD,  Prof Saad Z Usmani, MD,  Prof Sonja Zweegman, MD,  Sarah Holstein, MD,  Prof Orhan Sezer, MD,  Prof Simon Harrison, MD,  Hareth Nahi, MD,  Prof Gordon Cook, MD,  Maria-Victoria Mateos, MD,  Prof S Vincent Rajkumar, MD, Meletios A Dimopoulos, MD  Prof Paul G Richardson, MD

Citation:

The Lancet Oncology Volume 22, Issue 3, March 2021, Pages e105-e118
https://doi.org/10.1016/S1470-2045(20)30756-7